Polish Venture

Prospective companies apply directly by email. The fund's website describes a structured eight-stage funnel starting with a 2- to 4-week formal eligibility review. Beyond open applications, the firm's disclosed relationships with Polish universities and scientific-research units suggest an inbound pipeline from academic labs and technology-transfer offices.

It operates as a hybrid. The capital stack includes private funds alongside an allocation obtained through the NCBR Bridge Alfa competition, a Polish public program designed to bridge the gap between academic research and investable startups. This blend of private and public money shapes both the fund's longer risk tolerance and its proof-of-concept mandate.

The firm runs a proprietary sequence: after an initial formal review, it conducts proof-of-principle research — often commissioning external expert analyses at its own expense — then moves to full technical, IP, market, business-model, and team due diligence. The investment committee makes the final approval after reviewing the consolidated documentation.

The fund supplies portfolio companies with market research, product-strategy development, budgeting and financial-management support, HR assistance, and distribution-channel mapping. It also helps startups source follow-on financing for subsequent development stages, with an explicit goal of establishing them on Polish and international markets.

The firm's funnel excludes all non-medical projects. It requires every applicant to be a Poland-incorporated R&D project tied directly to medicine or telemedicine. Consumer software, industrial technology, clean energy, and generalist SaaS are outside the investment perimeter.